La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Talphera Croissance future
Future contrôle des critères 2/6
Talphera is forecast to grow earnings and revenue by 28.8% and 71.1% per annum respectively while EPS is expected to grow by 35.1% per annum.
Informations clés
28.8%
Taux de croissance des bénéfices
35.1%
Taux de croissance du BPA
Pharmaceuticals croissance des bénéfices | 23.6% |
Taux de croissance des recettes | 71.1% |
Rendement futur des capitaux propres | n/a |
Couverture par les analystes | Low |
Dernière mise à jour | 15 Aug 2024 |
Mises à jour récentes de la croissance future
Recent updates
AcelRx: The Catalogue Of Catalysts - Including A Big One That Will Do Investors Well
Aug 18AcelRx Pharmaceuticals: Finally, Plan B
Jun 06AcelRx Pharmaceuticals: Making Sense Of The Q4 Numbers
Mar 16AcelRx Pharmaceuticals: The Fog Is Getting Thicker
Jan 14AcelRx: Battered And Bruised But Ready For Recovery In 2022
Jan 05AcelRx Pharmaceuticals: Is Wayne Gretzky Right Or The Puck?
Oct 02AcelRx Pharmaceuticals: How The Licensing Agreements Could Become A Shot In The Arm
Jul 27FDA agrees with AcelRx to update promotional materials for Dsuvia
Jun 17Shareholders May Find It Hard To Justify Increasing AcelRx Pharmaceuticals, Inc.'s (NASDAQ:ACRX) CEO Compensation For Now
Jun 11AcelRx Pharmaceuticals: A Bullish View In 3 Song Titles
May 31Prévisions de croissance des bénéfices et des revenus
Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
---|---|---|---|---|---|
12/31/2026 | 7 | -24 | -15 | N/A | 3 |
12/31/2025 | 0 | -26 | -16 | N/A | 3 |
12/31/2024 | N/A | -19 | -9 | N/A | 3 |
6/30/2024 | 0 | -14 | N/A | N/A | N/A |
3/31/2024 | 1 | -14 | -15 | -15 | N/A |
12/31/2023 | 1 | -10 | -18 | -17 | N/A |
9/30/2023 | 0 | -11 | -19 | -19 | N/A |
6/30/2023 | 0 | -14 | -22 | -21 | N/A |
3/31/2023 | N/A | 58 | -25 | -25 | N/A |
12/31/2022 | N/A | 54 | -29 | -28 | N/A |
9/30/2022 | -2 | 69 | -31 | -31 | N/A |
6/30/2022 | -1 | 65 | -30 | -30 | N/A |
3/31/2022 | 2 | -31 | -31 | -29 | N/A |
12/31/2021 | 0 | -17 | -32 | -30 | N/A |
9/30/2021 | 4 | -36 | -32 | -28 | N/A |
6/30/2021 | 3 | -37 | -36 | -33 | N/A |
3/31/2021 | 6 | -33 | -36 | -34 | N/A |
12/31/2020 | 5 | -40 | -40 | -39 | N/A |
9/30/2020 | 5 | -46 | -47 | -46 | N/A |
6/30/2020 | 4 | -50 | -52 | -50 | N/A |
3/31/2020 | 2 | -55 | -55 | -52 | N/A |
12/31/2019 | 2 | -53 | -55 | -51 | N/A |
9/30/2019 | 2 | -51 | -49 | -46 | N/A |
6/30/2019 | 2 | -51 | -43 | -41 | N/A |
3/31/2019 | 2 | -49 | -36 | -35 | N/A |
12/31/2018 | 2 | -47 | -30 | -29 | N/A |
9/30/2018 | 2 | -44 | -27 | -27 | N/A |
6/30/2018 | 3 | -45 | -28 | -27 | N/A |
3/31/2018 | 5 | -48 | N/A | -30 | N/A |
12/31/2017 | 8 | -52 | N/A | -30 | N/A |
9/30/2017 | 14 | -51 | N/A | -33 | N/A |
6/30/2017 | 16 | -50 | N/A | -31 | N/A |
3/31/2017 | 17 | -48 | N/A | -31 | N/A |
12/31/2016 | 17 | -43 | N/A | -29 | N/A |
9/30/2016 | 13 | -44 | N/A | -12 | N/A |
6/30/2016 | 25 | -28 | N/A | -13 | N/A |
3/31/2016 | 22 | -25 | N/A | -15 | N/A |
12/31/2015 | 19 | -24 | N/A | -20 | N/A |
9/30/2015 | 18 | -28 | N/A | -36 | N/A |
6/30/2015 | 7 | -32 | N/A | -36 | N/A |
3/31/2015 | 5 | -34 | N/A | -35 | N/A |
12/31/2014 | 5 | -33 | N/A | -34 | N/A |
9/30/2014 | 33 | -2 | N/A | 0 | N/A |
6/30/2014 | 28 | -13 | N/A | -1 | N/A |
3/31/2014 | 29 | -20 | N/A | -1 | N/A |
12/31/2013 | 30 | -23 | N/A | 0 | N/A |
9/30/2013 | 4 | -52 | N/A | -32 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: TLPH is forecast to remain unprofitable over the next 3 years.
Bénéfices vs marché: TLPH is forecast to remain unprofitable over the next 3 years.
Croissance élevée des bénéfices: TLPH is forecast to remain unprofitable over the next 3 years.
Chiffre d'affaires vs marché: TLPH's revenue (71.1% per year) is forecast to grow faster than the US market (8.8% per year).
Croissance élevée des revenus: TLPH's revenue (71.1% per year) is forecast to grow faster than 20% per year.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Insufficient data to determine if TLPH's Return on Equity is forecast to be high in 3 years time